{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:03:22Z","timestamp":1794441802130,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117067","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T03:24:18Z","timestamp":1731986658000},"page":"117067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery of potent and selective factor XIa inhibitors incorporating triazole-based benzoic acid as novel P2\u2019 fragments: Molecular dynamics simulations and anticoagulant activity"],"prefix":"10.1016","volume":"282","author":[{"given":"Linjun","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boquan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-3596","authenticated-orcid":false,"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117067_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117067_bib2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117067_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.hoc.2016.06.002","article-title":"The history of antithrombotic therapy: the discovery of heparin, the vitamin K antagonists, and the utility of aspirin","volume":"30","author":"Handin","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2024.117067_bib4","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117067_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2023-184457","article-title":"A comparison of bleeding events among patients on apixaban, rivaroxaban, and warfarin for atrial fibrillation and\/or venous thromboembolism","volume":"142","author":"Schaefer","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117067_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical Guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejmech.2024.117067_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40265-024-02049-w","article-title":"Therapeutic potential of FXI inhibitors: hype or hope?","volume":"84","author":"Galli","year":"2024","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.117067_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","article-title":"Factor XI deficiency in humans","volume":"7","author":"Seligsohn","year":"2009","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2024.117067_bib9","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117067_bib10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ejmech.2024.117067_bib11","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1182\/blood.V128.22.3766.3766","article-title":"Bleeding in factor XI deficient mice","volume":"128","author":"Ay","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117067_bib12","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117067_bib13","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117067_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.122.061132","article-title":"What is the future of factor XI inhibitors?","volume":"146","author":"Weitz","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2024.117067_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2024.117067_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117067_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117067_bib18","unstructured":"A.T. News, https:\/\/anthostherapeutics.com\/anthos-therapeutics-novel-dual-acting-factor-xi-xia-inhibitor-abelacimab-150-mg-demonstrated-a-67-reduction-in-the-primary-endpoint-of-major-or-clinically-relevant-non-major-bleeding-compared-wi\/."},{"key":"10.1016\/j.ejmech.2024.117067_bib19","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","article-title":"Factor XIa inhibitors in anticoagulation therapy: recent advances and perspectives","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117067_bib21","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117067_bib22","unstructured":"Bayer, https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/."},{"key":"10.1016\/j.ejmech.2024.117067_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13787","article-title":"Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: a randomized dose-escalation phase I study","volume":"17","author":"Zhang","year":"2024","journal-title":"clin Transl Sci"},{"key":"10.1016\/j.ejmech.2024.117067_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1027627","article-title":"SHR2285, the first selectively oral FXIa inhibitor in China: safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117067_bib25","doi-asserted-by":"crossref","first-page":"e0196","DOI":"10.1097\/CCE.0000000000000196","article-title":"EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report","volume":"2","author":"Pollack","year":"2020","journal-title":"Crit. Care Explor."},{"key":"10.1016\/j.ejmech.2024.117067_bib26","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1021\/acs.jmedchem.0c00279","article-title":"Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: demonstrating the power of an integrated S1 protease family approach","volume":"63","author":"Lorthiois","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib27","doi-asserted-by":"crossref","first-page":"10419","DOI":"10.1021\/acs.jmedchem.2c00442","article-title":"Discovery of potent and orally bioavailable pyridine N-Oxide-Based factor XIa inhibitors through exploiting nonclassical interactions","volume":"65","author":"Xu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo- controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117067_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2024.117067_bib30","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib31","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2024.117067_bib32","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2024.117067_bib33","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117067_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13318-023-00838-4","article-title":"Metabolism and disposition of the novel oral factor XIa inhibitor asundexian in rats and in humans","volume":"48","author":"Piel","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.117067_bib35","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","article-title":"Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States","volume":"24","author":"Stepan","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117067_bib36","article-title":"Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments","author":"Zhang","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.117067_bib37","doi-asserted-by":"crossref","first-page":"B65","DOI":"10.1093\/eurheartjsupp\/suad070","article-title":"The new in anticoagulation: factor XI inhibitors","volume":"25","author":"Muscente","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"key":"10.1016\/j.ejmech.2024.117067_bib38","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2024.117067_bib39","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1002\/anie.201004575","article-title":"Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?","volume":"50","author":"Straub","year":"2011","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2024.117067_bib40","series-title":"L. Chengdu Taihe Weiye Biotechnology Co","article-title":"Preparation of heterocyclic amide derivatives as FXIa inhibitor and\/or plasma bradykinin kinase PKA inhibitor","author":"Xu","year":"2022"},{"key":"10.1016\/j.ejmech.2024.117067_bib41","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.117067_bib42","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants","volume":"61","author":"Quan","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib43","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.117067_bib44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117067_bib45","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/jm2010332","article-title":"Rational approaches to improving selectivity in drug design","volume":"55","author":"Huggins","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib46","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1021\/acs.jmedchem.2c00164","article-title":"Electrostatic complementarity in structure-based drug design","volume":"65","author":"Cons","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib47","series-title":"The Proteomics Protocols Handbook","first-page":"571","article-title":"Protein identification and analysis tools on the ExPASy server","author":"Gasteiger","year":"2005"},{"key":"10.1016\/j.ejmech.2024.117067_bib48","series-title":"Gaussian 16","author":"Frisch","year":"2016"},{"key":"10.1016\/j.ejmech.2024.117067_bib49","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib50","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1021\/acsmedchemlett.6b00384","article-title":"Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors","volume":"8","author":"Li","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117067_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1758-2946-6-12","article-title":"Protoss: a holistic approach to predict tautomers and protonation states in protein-ligand complexes","volume":"6","author":"Bietz","year":"2014","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2024.117067_bib53","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","article-title":"ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution","volume":"16","author":"Tian","year":"2020","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2024.117067_bib55","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1021\/ct200909j","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized born","volume":"8","author":"Gotz","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2024.117067_bib56","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/jcc.25382","article-title":"Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data","volume":"39","author":"Roe","year":"2018","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/jcc.21372","article-title":"Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA","volume":"31","author":"Rastelli","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.117067_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/pro.3280","article-title":"Improvements to the APBS biomolecular solvation software suite","volume":"27","author":"Jurrus","year":"2018","journal-title":"Protein Sci."},{"issue":"33\u201338","key":"10.1016\/j.ejmech.2024.117067_bib59","first-page":"27","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:18:18Z","timestamp":1733498298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424009498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":59,"alternative-id":["S0223523424009498"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117067","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent and selective factor XIa inhibitors incorporating triazole-based benzoic acid as novel P2\u2019 fragments: Molecular dynamics simulations and anticoagulant activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117067"}}